(Q36187022)

12 August 2017

1 reference

title

Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer (English)

1 reference

12 August 2017

1 reference

1

1 reference

12 August 2017

Elena Elstner

2

1 reference

PubMed ID

16004588

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

557-568

1 reference

12 August 2017

6

1 reference

Roles of PPARs in health and disease.

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Therapeutic potential of thiazolidinediones as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome-proliferator-activated receptors and cancers: complex stories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Can PPAR gamma ligands be used in cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Combining radiation and molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Telmisartan - killing two birds with one stone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor gamma (PPARgamma) binding and activation on some PPAR response elements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Activation of PPARgamma coactivator-1 through transcription factor docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

The Antiproliferative Effects of PPARγ Ligands in Normal Human Mammary Epithelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Terminal differentiation of human breast cancer through PPAR gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

In vivo activation of PPAR target genes by RXR homodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Peroxisome proliferator-activated receptor-binding protein null mutation results in defective mammary gland development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

PPAR gamma signaling exacerbates mammary gland tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.557

10.1517/13543784.14.6.557

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16004588